Robbert J. Kok

7.7k total citations
136 papers, 6.4k citations indexed

About

Robbert J. Kok is a scholar working on Molecular Biology, Biomaterials and Immunology and Allergy. According to data from OpenAlex, Robbert J. Kok has authored 136 papers receiving a total of 6.4k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Molecular Biology, 29 papers in Biomaterials and 25 papers in Immunology and Allergy. Recurrent topics in Robbert J. Kok's work include Nanoparticle-Based Drug Delivery (23 papers), Cell Adhesion Molecules Research (23 papers) and Angiogenesis and VEGF in Cancer (15 papers). Robbert J. Kok is often cited by papers focused on Nanoparticle-Based Drug Delivery (23 papers), Cell Adhesion Molecules Research (23 papers) and Angiogenesis and VEGF in Cancer (15 papers). Robbert J. Kok collaborates with scholars based in Netherlands, Germany and United States. Robbert J. Kok's co-authors include Wim E. Hennink, Grietje Molema, Gert Storm, Raymond M. Schiffelers, Kai Temming, Dirk K. F. Meijer, Roel Goldschmeding, Tri Q. Nguyen, Roy van der Meel and Ethlinn V.B. van Gaal and has published in prestigious journals such as Nano Letters, The Journal of Immunology and PLoS ONE.

In The Last Decade

Robbert J. Kok

136 papers receiving 6.3k citations

Peers

Countries citing papers authored by Robbert J. Kok

Since Specialization

Citations

This map shows the geographic impact of Robbert J. Kok's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robbert J. Kok with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robbert J. Kok more than expected).

Fields of papers citing papers by Robbert J. Kok

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robbert J. Kok. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robbert J. Kok. The network helps show where Robbert J. Kok may publish in the future.

Co-authorship network of co-authors of Robbert J. Kok

This figure shows the co-authorship network connecting the top 25 collaborators of Robbert J. Kok. A scholar is included among the top collaborators of Robbert J. Kok based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robbert J. Kok. Robbert J. Kok is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Utility of Intravenous Curcumin Nanodelivery Systems for Improving In Vivo Pharmacokinetics and Anticancer Pharmacodynamics 2022 ·Molecular Pharmaceutics ·Mahsa Bagheri, Cornelus F. van Nostrum, Robbert J. Kok, Gert Storm, Wim E. Hennink, Michal Heger	16
2	In Vitro and In Vivo Studies on HPMA-Based Polymeric Micelles Loaded with Curcumin 2021 ·Molecular Pharmaceutics ·Mahsa Bagheri, Marcel H.A.M. Fens, (unknown), Robin Capomaccio, Dóra Méhn, Przemek M. Krawczyk, (unknown), (unknown), Marc Baldus, (unknown), Robbert J. Kok, Michal Heger, Cornelus F. van Nostrum, Wim E. Hennink	42
3	Hyperthermia-triggered release of hypoxic cell radiosensitizers from temperature-sensitive liposomes improves radiotherapy efficacy in vitro 2019 ·Nanotechnology ·(unknown), Robbert J. Kok, Clemens Bos, Maurice M.J.M. Zandvliet, Willie J. C. Geerts, Gert Storm, Chrit Moonen, Twan Lammers, Roel Deckers	14
4	Sustained Release of Vascular Endothelial Growth Factor from Poly(ε-caprolactone-PEG-ε-caprolactone)-b-Poly(l-lactide) Multiblock Copolymer Microspheres 2019 ·ACS Omega ·(unknown), Roel F. Maas-Bakker, Thanh Tùng Nguyễn, (unknown), G. Hendriks, (unknown), Garry P. Duffy, Rob Steendam, Wim E. Hennink, Robbert J. Kok	28
5	Reversibly core-crosslinked PEG-P(HPMA) micelles: Platinum coordination chemistry for competitive-ligand-regulated drug delivery 2018 ·Journal of Colloid and Interface Science ·Sytze Buwalda, Benjamin Nottelet, Audrey Béthry, Robbert J. Kok, (unknown), Jean Coudane	25
6	Strategies for encapsulation of small hydrophilic and amphiphilic drugs in PLGA microspheres: State-of-the-art and challenges 2016 ·International Journal of Pharmaceutics ·Farshad Ramazani, (unknown), (unknown), Gert Storm, Fabian Kießling, Twan Lammers, Wim E. Hennink, Robbert J. Kok	226
7	Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma 2015 ·Clinical Cancer Research ·M. Emmy M. Dolman, Evon Poon, Marli E. Ebus, (unknown), Carel J.M. van Noesel, Yann Jamin, Albert Hallsworth, Simon P. Robinson, Kevin Petrie, Rolf W. Sparidans, Robbert J. Kok, Rogier Versteeg, Huib N. Caron, Louis Chesler, Jan J. Molenaar	47
8	Formulation and characterization of microspheres loaded with imatinib for sustained delivery 2015 ·International Journal of Pharmaceutics ·Farshad Ramazani, (unknown), (unknown), G. Storm, Fabian Kießling, Twan Lammers, Wim E. Hennink, Robbert J. Kok	52
9	Release and pharmacokinetics of near-infrared labeled albumin from monodisperse poly(d,l-lactic-co-hydroxymethyl glycolic acid) microspheres after subcapsular renal injection 2015 ·Acta Biomaterialia ·(unknown), (unknown), Dionne M. van der Giezen, (unknown), Farshad Ramazani, (unknown), G.J. Veldhuis, Roel Goldschmeding, Cornelus F. van Nostrum, Wim E. Hennink, Robbert J. Kok	8
10	Local therapeutic efficacy with reduced systemic side effects by rapamycin-loaded subcapsular microspheres 2014 ·Biomaterials ·Lucas L. Falke, (unknown), (unknown), Farshad Ramazani, Tri Q. Nguyen, G.J. Veldhuis, Erik M. van Maarseveen, (unknown), Johan Zuidema, (unknown), Rob Steendam, Eliane R. Popa, Robbert J. Kok, Roel Goldschmeding	41
11	Targeting tumors with nanobodies for cancer imaging and therapy 2013 ·Journal of Controlled Release ·Sabrina Oliveira, Raimond Heukers, (unknown), Robbert J. Kok, Paul M.P. van Bergen en Henegouwen	177
12	Nanobody-albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells 2012 ·Journal of Controlled Release ·Işıl Altıntaş, Raimond Heukers, Roy van der Meel, M. Lacombe, Maryam Amidi, Paul M.P. van Bergen en Henegouwen, Wim E. Hennink, Raymond M. Schiffelers, Robbert J. Kok	97
13	Controlled Release of Octreotide and Assessment of Peptide Acylation from Poly(D,L-lactide-co-hydroxymethyl glycolide) Compared to PLGA Microspheres 2011 ·Pharmaceutical Research ·Amir H. Ghassemi, Mies J. van Steenbergen, Arjan Barendregt, H. Talsma, Robbert J. Kok, Cornelus F. van Nostrum, Daan J.A. Crommelin, Wim E. Hennink	57
14	Local Inhibition of Liver Fibrosis by Specific Delivery of a Platelet-Derived Growth Factor Kinase Inhibitor to Hepatic Stellate Cells 2007 ·Journal of Pharmacology and Experimental Therapeutics ·Teresa Gonzalo, Leonie Beljaars, M. van de Bovenkamp, Kai Temming, (unknown), Catharina Reker‐Smit, Dirk K. F. Meijer, M. Lacombe, (unknown), Gÿorgý Kéri, László Őrfi, Klaas Poelstra, Robbert J. Kok	61
15	Antivascular Therapies: Targets Beyond the Vessel Wall 2007 ·ChemMedChem ·Kai Temming, Robbert J. Kok	3
16	Intracellular Delivery of the p38 Mitogen-Activated Protein Kinase Inhibitor SB202190 [4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1 H-imidazole] in Renal Tubular Cells: A Novel Strategy to Treat Renal Fibrosis 2006 ·Journal of Pharmacology and Experimental Therapeutics ·Jai Prakash, Maria Sandovici, Vinay Saluja, M. Lacombe, Roel Q.J. Schaapveld, Martin H. de Borst, Harry van Goor, Robert H. Henning, Johannes H. Proost, Frits Moolenaar, Gÿorgý Kéri, Dirk K. F. Meijer, Klaas Poelstra, Robbert J. Kok	53
17	Rational Design of RGD–Albumin Conjugates for Targeted Delivery of the VEGF‐R Kinase Inhibitor PTK787 to Angiogenic Endothelium 2006 ·ChemMedChem ·Kai Temming, M. Lacombe, Roel Q.J. Schaapveld, László Őrfi, Gÿorgý Kéri, Klaas Poelstra, Grietje Molema, Robbert J. Kok	29
18	Differential effects of NF-κB and p38 MAPK inhibitors and combinations thereof on TNF-α- and IL-1β-induced proinflammatory status of endothelial cells in vitro 2005 ·American Journal of Physiology-Cell Physiology ·(unknown), Johanna Westra, Sigrídur A. Ásgeirsdóttir, Robbert J. Kok, Koen Oosterhuis, Marianne G. Rots, Jan P. Schouten, Pieter C. Limburg, Grietje Molema	127
19	Selective Intracellular Delivery of Dexamethasone into Activated Endothelial Cells Using an E-Selectin-Directed Immunoconjugate 2002 ·The Journal of Immunology ·Maaike Everts, Robbert J. Kok, Sigrídur A. Ásgeirsdóttir, Barbro N. Melgert, (unknown), Gerben A. Koning, Marja J.A. van Luyn, Dirk K. F. Meijer, Grietje Molema	73
20	Targeting of RGD‐modified proteins to tumor vasculature: A pharmacokinetic and cellular distribution study 2002 ·International Journal of Cancer ·Astrid J. Schraa, Robbert J. Kok, Henk E. Moorlag, (unknown), Johannes H. Proost, Dirk K. F. Meijer, Lou F. M. H. de Leij, Grietje Molema	59

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact